Economics of Vaccine in England

Yuan Meng [1,†], Yapei Zhang [2,*,†]

[1] University of Pittsburgh, Pennsylvania, United States

[2.]University of California, Davis, United States

* Corresponding Author Email: zypzhang@ucdavis.edu

[†]These authors contributed equally.

Abstract. This study examines the economic effects of COVID-19 vaccine rollouts using a cross-country daily vaccination database and high-frequency indicators of economic activity—NO2 emissions, COemissions. We hitch go wool-gathering an uncourteous store in a hurry relative to a significant increase in productive activity. We anticipate contract hegemony for nonlinear emphatic vaccines, with insignificant remunerative profits increasing as vaccination rates rise. If absolute containment products are in place or if the country is experiencing a severe outbreak, country-specific issuance plays a primary role, resulting in far lower economic income. Surely, the consequences billet say-so of spillovers swelling vitality, highlighting the enumeration of equitable access to vaccines across nations. In addition, vaccines have a great impact on education, job employment rate, and people's quality of life. In education, many schools have changed the way of attending classes due to the epidemic, and the cost of attending classes has been reduced. At the same time, it also helps many people to develop and use video software. In addition, as the pandemic has affected the economy, many companies have faced closures and layoffs, leading to a significant decline in employment. We can't imagine how many people will lose their jobs as the companies they work for close down. A decline in employment leads to a loss of wages and reduced consumption, which in turn affects the economy as a whole. So vaccine development tends to increase employment, and companies can work when fewer people are sick. Therefore, it is necessary to discuss the health of the economy.

Keywords: economic, vaccines.

1. Introduction

Because COVID-19 has a great impact on the world and our lives, my friend in the UK got the new coronavirus, because she was not vaccinated, and her friends in the same dormitory, but she was not infected, after asking, his friend was vaccinated, so we want to discuss how much vaccine prevention against COVID-19.

The government of the United Kingdom has used a variety of methods to reduce the number of infected people, but vaccines are one of the most effective ways to reduce deaths and infections. So we are using this study to find out how people living in the UK are dealing with vaccines by observing how many people have been vaccinated.

2. Background

Rapid Covid-19 vaccination distribution in the four countries of the UK increased GDP by 2.1% in March, averting a sharp loss in the economy during the third lockdown in the first three months of the year.

The vaccine program allowed the government to start loosening limitations, and businesses responded to the limits more quickly than anticipated, causing the economy to contract by 1.5% during the first quarter of 2021, which was better than expected.

After the results from the Office for National Statistics showed that the pace of the economy was outpacing their predictions, city economists revised their growth projections for the remainder of the year.

There were worries earlier this year that the second virus wave in 2020 and a third lockdown would have a more negative impact on the economy and send the UK into a deep recession.

The economy's collapse was largely attributed to retail sales declines and school closings. As Covid limitations were loosened in March, growth resumed to all of the major economic sectors at a rate not seen since August 2020.

3. Literature References

Covid-19 vaccine acceptance is an important indicator to understand the vaccination rate in a country. Hence, behavioural economics can be used to analyse the relevant economic results [1]. Under the outbreak of Covid-19 pandemic, the increase of vaccination rate is economically meaningful, as it saves budgets for the country to treat infected patients [2]. The global Covid-19 vaccine market is expected to reach $62 billion by 2027 [3]. In Europe, the hesitation to use Covid-19 vaccine remains high, as people intend to make their own decision to get the vaccination out of their own will [4]. The delivery strategy of the policymakers need to the improved to ensure that the vaccines are well accepted in the UK [5]. The acceptance of Covid-19 vaccination depends on the knowledge about the effectiveness, which suggests that it is important for the supply chain to make efforts to seek the change [6]. The distribution of vaccine in the world to prevent the spread of Covid-19 pandemic is not even, which suggests that economic development level of the country influences the distribution of vaccines to the public [7]. The stakeholders identified to bear the costs of Covid-19 vaccination is an important factor influencing the acceptance of vaccination in the society [8]. For the provision of Covid-19 vaccine boosters, there are opinion from scientist that it is not sure whether it is needed, though the government might decide not to bear the costs for the citizens in the future [9]. To increase the vaccination rate, it is important to ensure that vaccine hesitancy needs to be overcome through social marketing. This is because people nowadays tend to be influenced by social media communication [10]. Although Covid-19 pandemic provides an opportunity to reduce the infection rate and death, it is necessary to point out that there are challenges for the government to understand when the entire supply chain and residents' opinions towards vaccination might be different [11].

4. Data

ACF series described the autocorrelation between one observation and another (Fig.1), and data in this image are of slowly decaying type, and it also shows the non-random linear trend. The residual sequence presents a stable trend, which conveys that after taking the first vaccine for Covid-19, the effects will present a slowly gradual downward trend. The specific data can be predicted based on its non-random linear trend. Hence, to be more resistant to the virus, the longer they have taken the first dose, the more necessary it is for them to take the subsequent ones.




Fig 1. ACF [12]

When looking at this PACF series (Fig.2), it is shown in a swiftly decaying type and seemingly the random linear trend. Beyond that, the plot reveals a crucial partial auto-correlation between 4 and 11, which instructs people to presume that the first dose of Covid-19 vaccines will last three months, and about a year later, the residual will only remain at 0.01. All these pieces of information efficiently convey the necessity for people to take the following doses three or four weeks after taking the first dose.




Fig 2. PACF [12]

The seven days rolling average indicates the average number of daily dosages taken by British people during the last seven days (Fig. 3). It showed a random linear trend, and it can conclude that more populations have taken the first dose as expected since the data presented a steadily reduced tendency since the third day. Even more remarkably, it reached 0e+00 on the last day of this rolling average period. It, to some extent, communicated that the government has got more people involved in taking the first dose of the vaccine.




Fig 3. seven days rolling average [12]

The p-value in this section is less than 0.05, indicating that the data is stationary. Furthermore, this provides evidence that vaccines have stable capabilities to prevent COVID-19.

5. ARIMA Modle

An autoregressive integrated moving average (ARIMA) model is a generalization of an autoregressive moving average (ARMA) model in statistics and econometrics, expecially in time series analysis. When data show some proof of non-stationarity in the sense of mean (but not variance/autocovariance), an initial differencing step can be applied one or more times to eliminate

the non-stationarity of the mean function. So we use this method to predict the future impact of the next first dose of vaccine on COVID-19, and we can calculate the trend of COVID-19 vaccine from the charts and the calculated data. It is already possible to guess whether the COVID-19 vaccine has an impact on the economy.

In the UK, residents die less with the first dose, especially in children and young people, thus proving that COVID-19 has a significant impact on mortality, ARIMA is the autoregressive, p is the autoregressive term, which can be estimated by seeing the autocorrelation graph; MA is the moving average, q is the moving average term number, you can see the partial correlation graph, d is the number of difference made when the time series becomes stable, here q is equal to 5, indicating that the average term number is 5.

As shown in the figure 4, the data rose at the beginning, about 2020 year, indicating that the number of people receiving the first dose of COVID-19 vaccine has increased sharply in a short period of time. Since the covide-19 has a big effect for the people ,and most of people very afraid of the covid-19.Then according to the image, as most people have been vaccinated and the COVID-19 epidemic has gradually eased, the number of people receiving the first dose will not increase, becoming a steady trend.




Fig 4. ARIMA

What we use in our modeling includes adftest, ARIMA and HOLTwith damping. Adftest is used to test whether the data is stationary. If the p-value is above 0.05, we will use difference method to make it stationary and apply ARIMA to model and forecast it. Besides, the data we utilize in our models are seven days rolling average, which shows weak seasonality.

p-value =[1-Φ(z0)].

6. Conclusion

To reduce the number of infected people, government of the U.K has applied many methods and vaccine is one of the most effective ways to reduce the number of death and getting affected. When we did this study, we found that the first dose of vaccine was very good at inhibiting COVID-19, and the British enthusiasm for the first dose of COVID-19, indicating that the government has taken good measures.

From our ARIMA and ACF data, it is also proved that the government adopts the vaccine measures that are effective. Subsequently, when increasingly individuals select to urge the primary shot of immunization, it shows that the mindfulness of COVID-19 has expanded, so we are able anticipate that each sound individual working effectively within the work will be accommodating for the financial advancement. We hope that our report will have some value.

At the end, we hope that COVID-19 will end soon, and we hope that people will be less affected by COVID-19. The economy and education will also show significant development and progress.

References

[1] Hursh, S. R., Strickland, J. C., Schwartz, L. P., & Reed, D. D. (2020). Quantifying the impact of public perceptions on vaccine acceptance using behavioral economics. Frontiers in public health, 8, 608852.

[2] Padula, W. V., Malaviya, S., Reid, N. M., Tierce, J., & Alexander, G. (2020). Economic value of treatment and vaccine to address the COVID-19 pandemic: a US cost-effectiveness and budget impact analysis. Available at SSRN 3586694.

[3] Shulman, J., Ahsan, R., & O'Malley, K. (2021). Understanding global vaccine economics and research and development. Powering Vaccine R&D: Opportunities for Transformation.

[4] Neumann-Böhme, S., Varghese, N. E., Sabat, I., Barros, P. P., Brouwer, W., van Exel, J., ... & Stargardt, T. (2020). Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. The European Journal of Health Economics, 21(7), 977-982.

[5] McPhedran, R., & Toombs, B. (2021). Efficacy or delivery? An online Discrete Choice Experiment to explore preferences for COVID-19 vaccines in the UK. Economics letters, 200, 109747.

[6] Alam, S. T., Ahmed, S., Ali, S. M., Sarker, S., & Kabir, G. (2021). Challenges to COVID-19 vaccine supply chain: Implications for sustainable development goals. International Journal of Production Economics, 239, 108193.

[7] Burki, T. (2021). Global COVID-19 vaccine inequity. The Lancet Infectious Diseases, 21(7), 922-923.

[8] Cerda, A. A., & García, L. Y. (2021). Willingness to pay for a COVID-19 vaccine. Applied health economics and health policy, 19(3), 343-351.

[9] Callaway, E. (2021). COVID vaccine boosters: the most important questions. Nature, 596(7871), 178-180.

[10] Evans, W. D., & French, J. (2021). Demand creation for COVID-19 vaccination: Overcoming vaccine hesitancy through social marketing. Vaccines, 9(4), 319.

[11] ElBagoury, M., Tolba, M. M., Nasser, H. A., Jabbar, A., Elagouz, A. M., Aktham, Y., & Hutchinson, A. (2021). The find of COVID-19 vaccine: Challenges and opportunities. Journal of infection and public health, 14(3), 389-416.

[12] RPubs https://rpubs.com/AngelicaFS/PST_STCM